Pulmonx (LUNG) Asset Writedowns and Impairment (2019 - 2025)
Pulmonx's (LUNG) quarterly Asset Writedowns and Impairment came in at $96000.0 in Q3 2025, up 165.75% year-on-year from $36123.7 in Q3 2024, and up 292.0% on a QoQ basis from -$50000.0 in Q2 2025.
Pulmonx (LUNG) Asset Writedowns and Impairment (2019 - 2025) Analysis & Trends
Pulmonx (LUNG) has 7 years of Asset Writedowns and Impairment data on file, last reported at $96000.0 in Q3 2025.
- On a quarterly basis, Asset Writedowns and Impairment rose 165.75% year-over-year to $96000.0 in Q3 2025; TTM through Jun 2025 was -$242000.0, a 110.21% decrease from a year earlier, with the FY2024 full-year figure at $1.7 million, up 238.66% from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $96000.0, up from -$50000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for LUNG reached as high as $1.7 million in Q2 2024 and fell as low as -$968000.0 in Q4 2021.
- Historically, Asset Writedowns and Impairment has averaged $134235.3 across 5 years, with a median of $65000.0 in 2022.
- Across the five-year window, Asset Writedowns and Impairment plunged 520.0% in 2023 and jumped 722.71% in 2024, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at -$968000.0 in 2021, then surged by 73.04% to -$261000.0 in 2022, then surged by 294.25% to $507000.0 in 2023, then slumped by 128.8% to -$146000.0 in 2024, then jumped by 165.75% to $96000.0 in 2025.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $96000.0 in Q3 2025, -$50000.0 in Q2 2025, and -$46000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pulmonx | 49.94 Mn | -19.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 96,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Jun 30, 2025 | -50,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Mar 31, 2025 | -46,000.00 |
| Sep 30, 2024 | -146,000.00 |
| Sep 30, 2024 | -146,000.00 |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 163,000.00 |
| Mar 31, 2024 | 163,000.00 |
| Dec 31, 2023 | 507,000.00 |
| Dec 31, 2023 | 507,000.00 |
| Jun 30, 2023 | -273,000.00 |
| Jun 30, 2023 | -273,000.00 |
| Mar 31, 2023 | 273,000.00 |
| Mar 31, 2023 | 273,000.00 |
| Dec 31, 2022 | -261,000.00 |
| Dec 31, 2022 | -261,000.00 |